Premium
Losartan therapy for cardiac disease in paediatric M arfan syndrome
Author(s) -
Ewans Lisa J,
Roberts Phillip,
Adès Lesley
Publication year - 2015
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.12823
Subject(s) - medicine , losartan , marfan syndrome , cardiology , disease , blockade , intensive care medicine , pediatrics , angiotensin ii , blood pressure , receptor
A case of severe early‐onset Marfan syndrome (MFS) led us to ask the question: ‘Should an ARB , particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?’ The current literature was critically appraised to address this question.